Hodgkin Lymphoma

Clinical Trials

Below is a list of Hodgkin Lymphoma clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
Patients are being asked to take part in this research study because they have cancer that has continued to grow despite the treatments they may have already received. Either the standard drugs used to treat their disease are no longer working or there are no known treatments that work because the patient's tumor cells may be resistant to these treatments. This clinical trial is about testing ZEN-012 which is a newly discovered chemical compound. It belongs to a group of drugs which may stop tumor cell growth.
This study is being done to:
- test the safety of ZEN-012 and see what effect (good and bad) it has on the patient and their cancer
- find the highest dose of ZEN-012 that can be given without causing bad side effects.

Read more

A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
Patients are being asked to take part in this research study because they have cancer that has continued to grow despite the treatments they may have already received. Either the standard drugs used to treat their disease are no longer working or there are no known treatments that work because the patient's tumor cells may be resistant to these treatments. This clinical trial is about testing ZEN-012 which is a newly discovered chemical compound. It belongs to a group of drugs which may stop tumor cell growth.

This study is being done to:
- Test the safety of ZEN-012 and see what effect (good and bad) it has on the patient and their cancer
- Find the highest dose of ZEN-012 that can be given without causing bad side
effects
Read more

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Sorafenib and RAD001 are two drugs that block some of the main switch pathways in tumor cells from working properly. When combined, it is hoped that they might prevent the cells from growing or cause them to die. Preliminary experiments with RAD001 in lymphoma patients have shown definite anti-tumor activity.
Read more

Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
The standard treatment for Hodgkin disease is chemotherapy and radiation therapy (high-dose x-rays). Most patients are cured of their Hodgkin disease, but some people have late effects from the treatment later in life. Late effects can include problems with growth, organ function, and sometimes a second kind of cancer. Late effects may be caused by either chemotherapy or radiation. Researchers believe that if some people can be treated with less treatment or with surgery alone, then these people might have fewer late effects.
This study is being done to:
- See if "late effects" (side effects that show up later in life from the treatment) can be lowered or prevented by using less chemotherapy and radiation.
- Find out if using less chemotherapy and radiation to treat LPHD will still show high cure rates or if cure rates will be lower than with standard treatment.
Read more